November 25^th, 2020

PROALT’s project proposal named ‘METASTCURE – Anti cadherin-RGD monoclonal antibody PA-0661 for the treatment of metastatic colorectal cancer’ has received the Seal of Excellence recognition from the Enhanced European Innovation Council (EIC) pilot in EU.

The EIC Accelerator programme is part of the Enhanced European Innovation Council pilot and provides grant and blended finance (grant in combination with equity investment) to high-risk, high-potential small and medium-sized innovative enterprises willing to develop and commercialise new products and business models that could drive economic growth and shape new markets or disrupt existing ones in Europe and worldwide.

METASTCURE project goal is to complete the pre-clinical phase of the lead therapeutic candidate PA-0661, a humanized monoclonal antibody against a novel target (cadherins RGD motif) that showed to be highly efficacious in the treatment of liver metastasis from colorectal cancer in animal models.